$403 Million

Supernus Pharmaceuticals

Convertible Debt

Bookrunner, March 2018

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

More Like This

Jan 2021
$69 Million

Convertible Notes Restructuring

Exclusive Financial Advisor

View Details >
Nov 2020
$197 Million
Tilray Logo

Convertible Notes Exchange

Exclusive Financial Advisor

View Details >
Nov 2020
$1.15 Billion

Convertible Debt

Co-Manager

View Details >